3 Penny Stocks to Watch Now, 12/4/25

Fitell Corporation (FTEL), Jasper Therapeutics (JSPR), and Boqii Holding (BQ) are highlighted as penny stocks to watch on December 4, 2025, using TipRanks’ Penny Stock Screener. This tool helps investors identify stocks by various filters, including Dollar Volume, which is the total value of shares traded in a day. TipRanks is offering a 60% discount on its Premium services for data-backed insights and research tools.

U.S. Stock Movement Update: Kala Bio up 24%, Cantor Equity Partners up 14%, Symbotic down 12%

The market overview of US stocks in the past hour shows that market sentiment fluctuates between the pharmaceutical and technology sectors, with pharmaceutical stocks performing particularly well. Kala Pharmaceuticals leads the way, indicating a preference for innovation in the pharmaceutical sector. Technology stocks, on the other hand, show divergence, with some individual stocks under pressure, as short-term funds seem to be searching for new breakthroughs. The overall pace is fast, with significant volatility, and short-term enthusiasm continues to rise. In the past hour, the stock with the largest movement is Kala Pharmaceuticals, which has become the market focus with a 24.32% increase, showing a clear influx of funds that has driven the stock price up rapidly. The active performance of the pharmaceutical sector appears to have sparked market interest in innovative drugs, with short-term sentiment running high. Strong stocks: 1. Cantor Equity Partners: up 13.94%, with significant fund inflow and investors full of expectations for future growth. 2. Moolec Science SA: up 10.93%, supported by the active performance of the biotechnology sector. 3. Davis Commodities: up 9.29%, benefiting from volatility in the commodities market. 4. UiPath: up 9.29%, driven by increasing demand for automation technology. 5. Brand Engagement Network: up 8.34%, with growing market interest in brand engagement technology. Stocks under pressure: 1. Symbotic: down 12.06%, facing pressure due to the divergence in the technology sector

RBC Capital Sticks to Its Hold Rating for Jasper Therapeutics (JSPR)

RBC Capital analyst Leonid Timashev maintained a Hold rating for Jasper Therapeutics with a $4.00 price target. William Blair also issued a Hold rating, while H.C. Wainwright maintained a Buy rating. Timashev, covering the Healthcare sector, has an average return of 29.3% and a 57.29% success rate on stock recommendations.

Jasper Therapeutics shares are trading higher after the company reported preliminary clinical data from Jasper's ETESIAN Phase 1b study of subcutaneous briquilimab in adult participants with allergic asthma.

Jasper Therapeutics Reports Positive Results For Briquilimab In Allergic Asthma Phase 1b Study

Jasper Therapeutics, Inc. reported positive preliminary results from its ETESIAN Phase 1b study of briquilimab in adults with allergic asthma. A single subcutaneous dose led to significant reductions in sputum eosinophils and improvements in FEV1. The drug was well tolerated, showing a favorable safety profile, supporting its continued development as a potential asthma treatment.